Drugs that contain Finerenone

1. Kerendia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 09, 2026
M(M-279) Sep 01, 2025

NCE-1 date: 09 July, 2025

Market Authorisation Date: 09 July, 2021

Treatment: NA


More Information on Dosage

KERENDIA family patents

Family Patents